Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. Dezember 2025 07:00 ET | Quelle: Comanche Biopharma

Comanche Biopharma Appoints Richard Colvin, MD, PhD as Global Head of R&D and John McHutchison, AO, MD as Chairman and Director of Comanche Biopharma Australia

Comanche Biopharma appoints Richard Colvin as Global Head of R&D, and John McHutchison as Chairman and Director, Comanche Biopharma Australia.
08. April 2025 07:00 ET | Quelle: Comanche Biopharma

Comanche Biopharma Announces European Medicines Agency (EMA) Has Granted Orphan Drug Designation for CBP-4888 in sFlt1-mediated Preterm Preeclampsia

Comanche Biopharma announces European Medicines Agency (EMA) has granted Orphan Drug Designation for CBP-4888 in sFlt1-mediated preterm preeclampsia.
30. Januar 2025 05:00 ET | Quelle: Comanche Biopharma

Comanche Biopharma Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway (ILAP) Steering Group for CBP-4888, an Investigational siRNA Drug Candidate for the Treatment of sFlt1-mediated Preterm Preeclampsia

Comanche awarded Innovation Passport designation by the U.K. Innovative Licensing and Access Pathway Steering Group for CBP-4888 to treat preeclampasia.
17. Januar 2024 06:00 ET | Quelle: Comanche Biopharma

Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia

Comanche Biopharma closes oversubscribed $75 Million Series B financing to advance first treatment targeting a root cause of preeclampsia.